Lactoferrin-Modified Gambogic Acid Liposomes for Colorectal Cancer Treatment.

Qianqian Li,Guihua Chen,Xueping Tang,Cai-hong Zheng,A. Ou,Yongzhuo Huang,Jingkun Qu,Jiaxin Zhang,Bahtiyor Muhitdinov,Rong Wang
DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00052
2023-07-28
Molecular Pharmaceutics
Abstract:Colorectal cancer (CRC) therapy is a big challenge, and seeking an effective and safe drug is a pressing clinical need. Gambogic acid is a potent antineoplastic agent without the drawback of bone marrow suppression. To improve its druggability (e.g., poor water solubility and tumor delivery), a lactoferrin-modified gambogic acid liposomal delivery system (LF-lipo) was developed to enhance the treatment efficacy of CRC. The LF-lipo can specifically bind LRP-1 expressed on colorectal cancer cells to enhance drug delivery to the tumor cells and yield enhanced therapeutic efficacy. The LF-lipo promoted tumor cell apoptosis and autophagy, reduced reactive oxygen species (ROS) levels in tumor cells, and inhibited angiogenesis; moreover, it could also repolarize tumor-associated macrophages from the M2 to M1 phenotype and induce ICD to activate T cells, exhibiting the capability of remodeling the tumor immune microenvironment. The liposomal formulation yielded an efficient and safe treatment outcome and has potential for clinical translation.
Medicine
What problem does this paper attempt to address?